ORC ID ">
  • Users Online: 4472
  • Home
  • Print this page
  • Email this page
RESEARCH ARTICLE
Year : 2021  |  Volume : 16  |  Issue : 2  |  Page : 312-318

Neuroprotection by cattle encephalon glycoside and ignotin beyond the time window of thrombolysis in ischemic stroke


1 Department of Neurosurgery, Southwest Hospital, The Third Military Medical University (Army Medical University), Chongqing, China
2 Department of Neurosurgery, Southwest Hospital, The Third Military Medical University (Army Medical University), Chongqing; Department of Neurosurgery, Hanzhong Central Hospital, Hanzhong, Shaanxi Province, China
3 Department of Oncology, Hanzhong Central Hospital, Hanzhong, Shaanxi Province, China
4 Department of Neurosurgery, Southwest Hospital, The Third Military Medical University (Army Medical University); State Key Laboratory of Power Transmission Equipment and System Security and New Technology, School of Electrical Engineering, Chongqing University, Chongqing, China

Correspondence Address:
Liang Tan
Department of Neurosurgery, Southwest Hospital, The Third Military Medical University (Army Medical University); State Key Laboratory of Power Transmission Equipment and System Security and New Technology, School of Electrical Engineering, Chongqing University, Chongqing
China
Login to access the Email id

Source of Support: This study was supported by the 63rd Batch of First-Class Financing for Chinese Postdoctoral Science Foundation, No. 2018M631061 (to LT) and Macao Youth Scholars Program, No. AM201918 (to LT), Conflict of Interest: None


DOI: 10.4103/1673-5374.290899

Rights and Permissions

Cattle encephalon glycoside and ignotin (CEGI) injection is known as a multi-target neuroprotective drug that contains numerous liposoluble molecules, such as polypeptides, monosialotetrahexosyl ganglioside (GM-1), free amino acids, hypoxanthine and carnosine. CEGI has been approved by the Chinese State Food and Drug Administration and widely used in the treatments of various diseases, such as stroke and Alzheimer's disease. However, the neuroprotective effects of CEGI beyond the time window of thrombolysis (within 4.5 hours) on acute ischemic stroke remain unclear. This study constructed a rat middle cerebral artery occlusion model by suture-occluded method to simulate ischemic stroke. The first daily dose was intraperitoneally injected at 8 hours post-surgery and the CEGI treatments continued for 14 days. Results of the modified five-point Bederson scale, beam balance test and rotameric test showed the neurological function of ischemic stroke rats treated with 4 mL/kg/d CEGI improved significantly, but the mortality within 14 days did not change significantly. Brain MRI and 2,3,5-triphenyltetrazolium chloride staining confirmed that the infarct size in the 4 mL/kg/d CEGI-treated rats was significantly reduced compared with ischemic insult only. The results of transmission electron microscopy and double immunofluorescence staining showed that the hippocampal neuronal necrosis in the ischemic penumbra decreased whereas the immunopositivity of new neuronal-specific protein doublecortin and the percentage of Ki67/doublecortin positive cells increased in CEGI-treated rats compared with untreated rats. Our results suggest that CEGI has an effective neuroprotective effect on ischemic stroke when administered after the time window of thrombolysis. The study was approved by the Animal Ethics Committee of The Third Military Medical University, China.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed278    
    Printed0    
    Emailed0    
    PDF Downloaded101    
    Comments [Add]    

Recommend this journal